- Home
- NERV vs BRTX Comparison
NERV vs BRTX Comparison
Compare NERV & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- BRTX
- Stock Information
- Founded
- NERV 2007
- BRTX 1997
- Country
- NERV United States
- BRTX United States
- Employees
- NERV N/A
- BRTX N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- NERV Health Care
- BRTX Health Care
- Exchange
- NERV Nasdaq
- BRTX Nasdaq
- Market Cap
- NERV 12.6M
- BRTX 12.6M
- IPO Year
- NERV 2014
- BRTX N/A
- Fundamental
- Price
- NERV $1.73
- BRTX $1.58
- Analyst Decision
- NERV Hold
- BRTX Strong Buy
- Analyst Count
- NERV 1
- BRTX 1
- Target Price
- NERV $5.00
- BRTX $18.00
- AVG Volume (30 Days)
- NERV 12.1K
- BRTX 255.9K
- Earning Date
- NERV 08-05-2025
- BRTX 08-12-2025
- Dividend Yield
- NERV N/A
- BRTX N/A
- EPS Growth
- NERV N/A
- BRTX N/A
- EPS
- NERV 0.83
- BRTX N/A
- Revenue
- NERV N/A
- BRTX $391,000.00
- Revenue This Year
- NERV N/A
- BRTX $391.52
- Revenue Next Year
- NERV N/A
- BRTX $3.50
- P/E Ratio
- NERV $2.06
- BRTX N/A
- Revenue Growth
- NERV N/A
- BRTX 161.54
- 52 Week Low
- NERV $1.15
- BRTX $1.21
- 52 Week High
- NERV $3.50
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NERV 50.22
- BRTX 42.38
- Support Level
- NERV $1.57
- BRTX $1.57
- Resistance Level
- NERV $1.88
- BRTX $1.72
- Average True Range (ATR)
- NERV 0.09
- BRTX 0.10
- MACD
- NERV -0.02
- BRTX -0.01
- Stochastic Oscillator
- NERV 52.03
- BRTX 6.33
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.